Abstract:Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by motor neuron degeneration that ultimately results in progressive paralysis and death. Growing evidence indicates that mitochondrial dysfunction and oxidative stress contribute to motor neuron degeneration in ALS. To further explore the hypothesis that mitochondrial dysfunction and nitroxidative stress contribute to disease pathogenesis at the in vivo level, we assessed whether the mitochondria-targeted antioxidant [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium methane sulfonate (MitoQ) can modify disease progression in the SOD1(G93A) mouse model of ALS. To do this, we administered MitoQ (500 µM) in the drinking water of SOD1(G93A) mice from a time when early symptoms of neurodegeneration become evident at 90 days of age until death. This regime is a clinically plausible scenario and could be more easily translated to patients as this corresponds to initiating treatment of patients after they are first diagnosed with ALS. MitoQ was detected in all tested tissues by liquid chromatography/mass spectrometry after 20 days of administration. MitoQ treatment slowed the decline of mitochondrial function, in both the spinal cord and the quadriceps muscle, as measured by high-resolution respirometry. Importantly, nitroxidative markers and pathological signs in the spinal cord of MitoQ-treated animals were markedly reduced and neuromuscular junctions were recovered associated with a significant increase in hindlimb strength. Finally, MitoQ treatment significantly prolonged the life span of SOD1(G93A) mice. Our results support a role for mitochondrial nitroxidative damage and dysfunction in the pathogenesis of ALS and suggest that mitochondria-targeted antioxidants may be of pharmacological use for ALS treatment.

The Role of Mitochondria-Targeted Antioxidant MitoQ in Neurodegenerative Disease

Mitochondrial Dysfunction in Microglia: a Novel Perspective for Pathogenesis of Alzheimer’s Disease

Targeting Mitochondrial Dysfunction and Reactive Oxygen Species for Neurodegenerative Disease Treatment

Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis

Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons

Mitochondria-targeted TPP-MoS2 with dual enzyme activity provides efficient neuroprotection through M1/M2 microglial polarization in an Alzheimer's disease model

Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer's disease.

Reducing Mitochondrial Decay with Mitochondrial Nutrients to Delay and Treat Cognitive Dysfunction, Alzheimer's Disease, and Parkinson's Disease

Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances

Mitochondrial dysfunction in microglia: a novel perspective for pathogenesis of Alzheimer's disease

Progress in mitochondrial and omics studies in Alzheimer's disease research: from molecular mechanisms to therapeutic interventions

Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update

Molecular mechanisms of mitochondrial homeostasis regulation in neurons and possible therapeutic approaches for Alzheimer's disease

Therapeutic Targeting of Mitochondria-Proteostasis Axis by Antioxidant Polysaccharides in Neurodegeneration.

Modulation of Mitochondrial Function as a Therapeutic Strategy for Neurodegenerative Diseases

Role of mitophagy in mitochondrial quality control: Mechanisms and potential implications for neurodegenerative diseases

Mitophagy in Alzheimer’s Disease and Other Age-Related Neurodegenerative Diseases

Mitochondria-Targeted Drugs

Mitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease

Role of Mitophagy in neurodegenerative Diseases and potential tagarts for Therapy

Mechanisms of Mitochondrial Malfunction in Alzheimer's Disease: New Therapeutic Hope